# Protocol for morphogen-guided differentiation of brain cell types using human induced pluripotent stem cells

**Authors:** Lu Qian, Juao-Guilherme Rosa, Julia TCW

PMC · DOI: 10.1016/j.xpro.2025.104339 · 2026-01-16

## TL;DR

This paper provides a detailed protocol for differentiating human stem cells into brain cell types to study neurological disorders.

## Contribution

A novel protocol for morphogen-guided differentiation of hiPSCs into microglia, astrocytes, and mixed cortical cultures is introduced.

## Key findings

- Hypoxia enhances microglial production from hiPSCs.
- Serum-free astrocyte differentiation is achieved using knockout serum replacement.
- Quality-control measures improve differentiation outcomes for astrocytes and mixed cortical cultures.

## Abstract

Modeling neurological disorders is challenging due to differing functional genomics and phenotypes among species. Here, we present a protocol for morphogen-guided differentiation of human induced pluripotent stem cells (hiPSCs) into microglia, astrocytes, and mixed cortical cultures (MCCs) for studying human brain disorders. We describe steps for enhancing microglial production using hypoxia and implementing quality-control measures for astrocyte and MCC differentiations. We detail knockout serum replacement procedures for serum-free astrocytes. This protocol enables cell-type-specific investigation of disease mechanisms and drug screening.

•Guidance for morphogen- and small-molecule differentiation of human iPSC neural cultures•Steps for hypoxia-facilitated differentiation of hematopoietic progenitors at high yield•Instructions for serum-free astrocyte differentiation•Procedures for troubleshooting neural differentiation with contaminant cell types

Guidance for morphogen- and small-molecule differentiation of human iPSC neural cultures

Steps for hypoxia-facilitated differentiation of hematopoietic progenitors at high yield

Instructions for serum-free astrocyte differentiation

Procedures for troubleshooting neural differentiation with contaminant cell types

Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.

Modeling neurological disorders is challenging due to differing functional genomics and phenotypes among species. Here, we present a protocol for morphogen-guided differentiation of human induced pluripotent stem cells (hiPSCs) into microglia, astrocytes, and mixed cortical cultures (MCCs) for studying human brain disorders. We describe steps for enhancing microglial production using hypoxia and implementing quality-control measures for astrocyte and MCC differentiation. We detail knockout serum replacement procedures for serum-free astrocytes. This protocol enables cell-type-specific investigation of disease mechanisms and drug screening.

## Full-text entities

- **Genes:** CX3CR1 (C-X3-C motif chemokine receptor 1) [NCBI Gene 1524] {aka CCRL1, CMKBRL1, CMKDR1, GPR13, GPRV28, V28}, ITGA2B (integrin subunit alpha 2b) [NCBI Gene 3674] {aka BDPLT16, BDPLT2, CD41, CD41B, FMAIT2, GP2B}, CD200 (CD200 molecule) [NCBI Gene 4345] {aka MOX1, MOX2, MRC, OX-2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, TMEM119 (transmembrane protein 119) [NCBI Gene 338773] {aka OBIF}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, BMP4 (bone morphogenetic protein 4) [NCBI Gene 652] {aka BMP2B, BMP2B1, MCOPS6, OFC11, ZYME}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, AQP4 (aquaporin 4) [NCBI Gene 361] {aka MIWC, MLC4, WCH4, hAQP4}, CX3CL1 (C-X3-C motif chemokine ligand 1) [NCBI Gene 6376] {aka ABCD-3, C3Xkine, CXC3, CXC3C, NTN, NTT}, NPC1 (NPC intracellular cholesterol transporter 1) [NCBI Gene 4864] {aka NPC, POGZ, SLC65A1}, SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688] {aka AGM10, OF, PU.1, SFPI1, SPI-1, SPI-A}, SPN (sialophorin) [NCBI Gene 6693] {aka CD43, GALGP, GPL115, LEU-22, LSN}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, BMP1 (bone morphogenetic protein 1) [NCBI Gene 649] {aka OI13, PCOLC, PCP, TLD}, IL34 (interleukin 34) [NCBI Gene 146433] {aka C16orf77, IL-34}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, MAP2 (microtubule associated protein 2) [NCBI Gene 4133] {aka MAP-2, MAP2A, MAP2B, MAP2C}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, VIM (vimentin) [NCBI Gene 7431], SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, FOXP1 (forkhead box P1) [NCBI Gene 27086] {aka 12CC4, HSPC215, MFH, QRF1, hFKH1B}, NGFR (nerve growth factor receptor) [NCBI Gene 4804] {aka CD271, Gp80-LNGFR, TNFRSF16, p75(NTR), p75NTR}, MCC (MCC regulator of Wnt signaling pathway) [NCBI Gene 4163] {aka MCC1}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, CD34 (CD34 molecule) [NCBI Gene 947], GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209] {aka AD17, PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c}, TPO (thyroid peroxidase) [NCBI Gene 7173] {aka MSA, TDH2A, TPX}, PAX6 (paired box 6) [NCBI Gene 5080] {aka AN, AN1, AN2, ASGD5, D11S812E, FVH1}, P2RY12 (purinergic receptor P2Y12) [NCBI Gene 64805] {aka ADPG-R, BDPLT8, HORK3, P2T(AC), P2Y(12)R, P2Y(AC)}
- **Diseases:** hypoxic (MESH:D002534), neurodegenerative diseases (MESH:D019636), mycoplasma (MESH:D009175), brain disorders (MESH:D001927), inflammatory (MESH:D007249), HPCs (MESH:D019337), neurological disorders (MESH:D009461), AD (MESH:D000544), HPC (MESH:C537243), Hypoxia (MESH:D000860)
- **Chemicals:** CD lipid concentrate (-), P (MESH:D010758), MTG (MESH:C009465), S (MESH:D013455), L-Ascorbic Acid (MESH:D001205), ITS-X (MESH:C403901), PVA (MESH:D011142), N2 (MESH:D009584), calcium (MESH:D002118), lipid (MESH:D008055), LiCl (MESH:D018021), GlutaMax (MESH:C054122), DAPI (MESH:C007293), cholesterol (MESH:D002784), phenol (MESH:D019800), AGS (MESH:D012834), CO2 (MESH:D002245), LDN 193189 (MESH:C554430), Trypan blue (MESH:D014343), water (MESH:D014867), Thiazovivin (MESH:C545214), DMSO (MESH:D004121), Vitamin A (MESH:D014801), ATP (MESH:D000255), ice (MESH:D007053), AMPA (MESH:D018350), O2 (MESH:D010100), F12 (MESH:C007782), SB431542 (MESH:C459179), GABA (MESH:D005680), DPBS (MESH:C012939)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** KOLF2.1J — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_B5P3)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12856185/full.md

---
Source: https://tomesphere.com/paper/PMC12856185